Grade: Pharmaceutical Grade

Factory Location: QUANZHOU

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Sample Provided: no

Bictegravir is a novel integrase inhibitor developed by Gilead Sciences scientists. In vitro and clinical results were produced by Gilead in the summer of 2016. As of June 2016, Bictegravir was used as a single tablet regimen in combination with tenofovir alafinamide (TAF) and emtricitabine (FTC) for the treatment of hiv-1 infection.

Indication: HIV-1 infection

All the products under the patent are only for R&D use.

Patent from Gilead Sciences, expiry date(The U.S):Dec.19,2033